#UlcerativeColitis #Mirikizumab #UC #IL23
#Immunotherapy #Gastroenterology
Ulcerative colitis (UC) is a
chronic
inflammatory bowel disease characterized by continuous inflammation of the
recto-colonic mucosa, leading to debilitating symptoms such as
abdominal pain,
rectal bleeding, chronic diarrhea, and impaired quality of life. Although many
therapeutic options have emerged over the past two decades—including
anti-TNF
agents, anti-integrins, JAK inhibitors, sphingosine-1-phosphate modulators, and
ustekinumab—rates of
primary failure or
secondary loss of response remain high.
Up to
50% of patients either do not respond or fail to maintain a long-term
therapeutic response. In refractory cases,
surgery (colectomy) is still
required in about
15% of cases, often resulting in significant functional
consequences.
Against this complex therapeutic backdrop,
recent attention has turned to
the interleukin-23 (IL-23) pathway, a key
cytokine involved in the differentiation of Th17 lymphocytes, which plays a
major role in the pathophysiology of UC.
Mirikizumab, a monoclonal antibody
that specifically targets the p19 subunit of IL-23, may therefore offer an
innovative, more targeted, and potentially better-tolerated alternative to
previous approaches.
This study was designed to evaluate the
clinical, endoscopic, and histological efficacy of mirikizumab, as well as its
safety profile compared to placebo.
Mirikizumab: finally the right answer?
For this study, four multicenter randomized
clinical trials involving
over 2,350 patients with moderate to severe UC were
selected. Induction therapy was administered intravenously (IV), followed by
maintenance therapy in a subcutaneous (SC) form. Efficacy criteria included
clinical remission (Mayo score ≤ 2), clinical response, endoscopic and
histological remission, and symptomatic remission.
Results showed
clear superiority of mirikizumab
over placebo. During the induction phase, IV doses of 200 mg and 300 mg led to
significant clinical remission (RR = 4.74 and 1.82, respectively). For
maintenance therapy, clinical remission at 52 weeks was achieved in 49.9% of
patients versus 25.1% in the placebo group. The treatment effects were also
significant for
clinical response (RR = 2.01),
endoscopic remission (RR =
1.92), and
histological remission (RR = 1.84). Sensitivity analyses, excluding
studies at high risk of bias, confirmed the robustness of the findings.
In terms of
tolerability, adverse event rates
were similar between groups. A few isolated cases of opportunistic infections
or liver enzyme elevations were reported, without any major safety signals. The
discontinuation rate due to adverse events was lower in the mirikizumab group
compared to placebo (RR = 0.23).
Read next: Intestine–pancreas: a confirmed connection
A game-changing new option
Ulcerative colitis is a chronic inflammatory
condition of the colon marked by persistent inflammation of the digestive
mucosa. Despite therapeutic advances, it remains a
true clinical
challenge—particularly in patients who
fail conventional biologic therapies
such as anti-TNF agents or JAK inhibitors. These refractory cases require
effective, long-lasting, and well-tolerated alternatives.
The goal of this study was to
evaluate the
clinical, endoscopic, and histological efficacy of mirikizumab, an
anti-IL-23p19 antibody, in patients with moderate to severe UC, as well as its
safety compared to placebo. The results confirm that mirikizumab leads to
significant and sustained improvement in disease activity markers. It also
demonstrates a
favorable safety profile, with fewer treatment discontinuations
due to adverse events compared to placebo. These data position mirikizumab as a
serious therapeutic option, particularly relevant for patients who have failed
multiple prior treatments.
Future prospects include conducting
head-to-head trials against other IL-23 inhibitors,
more precise stratification
of naïve vs. previously exposed patients, and
identifying predictive biomarkers
of response. If confirmed, mirikizumab could become a
future standard of care
for moderate to severe UC, especially in treatment-resistant scenarios.
Read next: IBD: a double burden
